Hemostatic factors, APOL1 risk variants, and the risk of ESRD in the atherosclerosis risk in communities study

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 5, 2015, Pages 784-790

  Tin, Adrienne ^a   Grams, Morgan E ^b   Maruthur, Nisa M ^b   Astor, Brad C ^c   Couper, David ^d   Mosley, Thomas H ^e   Fornage, Myriam ^f   Parekh, Rulan S ^g   Coresh, Josef ^a   Linda Kao, Wen Hong ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d IL   (United States)

^e UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; APOLIPOPROTEIN; APOLIPOPROTEIN L1; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7C; BLOOD CLOTTING FACTOR 8C; FIBRINOGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN C; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; APOL1 PROTEIN, HUMAN; BLOOD CLOTTING FACTOR 8; HIGH DENSITY LIPOPROTEIN;

ADULT; ALLELE; ANCESTRY GROUP; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; ELECTROCARDIOGRAPHY; END STAGE RENAL DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENE FREQUENCY; GENOTYPING TECHNIQUE; GLOMERULUS FILTRATION RATE; HEMOSTASIS; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MISSENSE MUTATION; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; AFRICAN AMERICAN; BLOOD; CAUCASIAN; GENETICS; KIDNEY FAILURE, CHRONIC; METABOLISM; RISK ASSESSMENT; RISK FACTOR; STATISTICS AND NUMERICAL DATA; UNITED STATES;

AFRICAN AMERICANS; ALLELES; ANTITHROMBIN III; APOLIPOPROTEINS; BLOOD COAGULATION FACTORS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FACTOR VIII; FEMALE; FIBRINOGEN; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PROTEIN C; RISK ASSESSMENT; RISK FACTORS; UNITED STATES; VON WILLEBRAND FACTOR;

EID: 84929162526     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.08340814     Document Type: Article

References (45)

1. NKUDIC: KidneyDisease Statistics for the United States fromthe National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC). Available at: http://kidney.niddk.nih.gov/kudiseases/pubs/kustats. Accessed April 15, 2014.
2. Bash LD, Erlinger TP, Coresh J, Marsh-Manzi J, Folsom AR, Astor BC: Inflammation, hemostasis, and the risk of kidney function decline in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 53: 596–605, 2009
3. Fried L, Solomon C, Shlipak M, Seliger S, Stehman-Breen C, Bleyer AJ, Chaves P, Furberg C, Kuller L, Newman A: Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J Am Soc Nephrol 15: 3184–3191, 2004
4. Rifkin DE, Sarnak MJ: Does inflammation fuel the fire in CKD? Am J Kidney Dis 53: 572–575, 2009
5. Hiramoto JS, Katz R, Peralta CA, Ix JH, Fried L, Cushman M, Siscovick D, Palmas W, Sarnak M, Shlipak MG: Inflammation and coagulation markers and kidney function decline: the Multi- Ethnic Study of Atherosclerosis (MESA). AmJ KidneyDis 60: 225–232, 2012
6. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL, Bernhardy AJ, Hicks PJ, Nelson GW, Vanhollebeke B, Winkler CA, Kopp JB, Pays E, Pollak MR: Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329: 841–845, 2010
7. Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekegn A, Bekele E, Bradman N, Wasser WG, Behar DM, Skorecki K: Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 128: 345–350, 2010
8. Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, Feldman HI, Parekh RS, Kusek JW, Greene TH, Fink JC, Anderson AH, Choi MJ, Wright JT Jr, Lash JP, Freedman BI, Ojo A, Winkler CA, Raj DS, Kopp JB, He J, Jensvold NG, Tao K, Lipkowitz MS, Appel LJ; AASK Study Investigators; CRIC Study Investigators: APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 369: 2183–2196, 2013
9. Foster MC, Coresh J, Fornage M, Astor BC, Grams M, Franceschini N, Boerwinkle E, Parekh RS, Kao WH: APOL1 variants associate with increased risk of CKD among African Americans. J Am Soc Nephrol 24: 1484–1491, 2013
10. Freedman BI, Skorecki K: Gene-gene and gene-environment interactions in apolipoprotein L1 gene-associated nephropathy. Clin J Am Soc Nephrol 9: 2006–2013, 2014
11. Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S, Mokrzycki MH, Kimmel PL, Limou S, Ahuja TS, Berns JS, Fryc J, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Vlahov D, Pollak M, Winkler CA: APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 22: 2129–2137, 2011
12. Estrella MM, Li M, Tin A, Abraham AG, Shlipak MG, Penugonda S, Hussain SK, Palella FJ Jr, Wolinsky SM, Martinson JJ, Parekh RS, Kao WH: The association between APOL1 risk alleles and longitudinal kidney function differs by HIV viral suppression status [published online ahead of print October 5, 2014]. Clin Infect Dis doi: 10.1093/cid/ciu765
13. Taylor HE, Khatua AK, Popik W: The innate immune factor apolipoprotein L1 restricts HIV-1 infection. J Virol 88: 592–603, 2014
14. Lan X, Jhaveri A, Cheng K, Wen H, Saleem MA, Mathieson PW, Mikulak J, Aviram S, Malhotra A, Skorecki K, Singhal PC: APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability. Am J Physiol Renal Physiol 307: F326–F336, 2014
15. Nichols B, Jog P, Lee JH, Blackler D, Wilmot M, D’Agati V, Markowitz G, Kopp JB, Alper SL, Pollak MR, Friedman DJ: Innate immunity pathways regulate the nephropathy gene apolipoprotein L1 [Published online ahead of print August 6, 2014]. Kidney Int doi: 10.1038/ki.2014.270
16. Thomson R, Genovese G, Canon C, Kovacsics D, Higgins MK, Carrington M, Winkler CA, Kopp J, Rotimi C, Adeyemo A, Doumatey A, Ayodo G, Alper SL, Pollak MR, Friedman DJ, Raper J: Evolution of the primate trypanolytic factor APOL1. Proc Natl Acad Sci U S A 111: E2130–E2139, 2014
17. ARIC: The Atherosclerosis Risk in Communities (ARIC) Study: Design and objectives. The ARIC investigators. Am J Epidemiol 129: 687–702, 1989
18. Sharrett AR: The Atherosclerosis Risk in Communities (ARIC) Study. Introduction and objectives of the hemostasis component. Ann Epidemiol 2: 467–469, 1992
19. Papp AC, Hatzakis H, Bracey A, Wu KK: ARIChemostasis study— I. Development of a blood collection and processing system suitable for multicenter hemostatic studies. Thromb Haemost 61: 15–19, 1989
20. Wu KK, Papp AC, Patsch W, Rock R, Eckfeldt J, Sharrett R: ARIC hemostasis study—II. Organizational plan and feasibility study. Thromb Haemost 64: 521–525, 1990
21. Chambless LE, McMahon R, Wu K, Folsom A, Finch A, Shen YL: Short-term intraindividual variability in hemostasis factors. The ARIC Study. Atherosclerosis Risk in Communities Intraindividual Variability Study. Ann Epidemiol 2: 723–733, 1992
22. Genovese G, Friedman DJ, Pollak MR: APOL1 variants and kidney disease in people of recent African ancestry. Nat Rev Nephrol 9: 240–244, 2013
23. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC: PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559–575, 2007
24. O’Seaghdha CM, Parekh RS, Hwang SJ, Li M, Köttgen A, Coresh J, Yang Q, Fox CS, Kao WH: TheMYH9/APOL1 region and chronic kidney disease in European-Americans. Hum Mol Genet 20: 2450–2456, 2011
25. Friedman DJ, Kozlitina J, Genovese G, Jog P, Pollak MR: Population-based risk assessment of APOL1 on renal disease. J Am Soc Nephrol 22: 2098–2105, 2011
26. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499–502, 1972
27. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604–612, 2009
28. Matsushita K, Selvin E, Bash LD, Astor BC, Coresh J: Risk implications of the new CKD Epidemiology Collaboration (CKDEPI) equation compared with the MDRD Study equation for estimated GFR: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 55: 648–659, 2010
29. Kidney Disease: Improving Global Outcome (KDIGO) CKD Work Group: KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3: 1–150, 2013
30. Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, Levin A, Levey AS: A predictive model for progression of chronic kidney disease to kidney failure. JAMA 305: 1553–1559, 2011
31. Kisiel W: Human plasma protein C: isolation, characterization, andmechanism of activation by alpha-thrombin. J Clin Invest 64: 761–769, 1979
32. Fay PJ: Activation of factor VIII and mechanisms of cofactor action. Blood Rev 18: 1–15, 2004
33. Marlar RA, Kleiss AJ, Griffin JH: Human protein C: inactivation of factors V and VIII in plasma by the activated molecule. Ann N Y Acad Sci 370: 303–310, 1981
34. Levi M, van der Poll T, Bu¨ ller HR: Bidirectional relation between inflammation and coagulation. Circulation 109: 2698–2704, 2004
35. Madhavan SM, O’Toole JF, Konieczkowski M, Ganesan S, Bruggeman LA, Sedor JRCINJASNN: APOL1 localization in normal kidney and nondiabetic kidney disease. J Am Soc Nephrol 22: 2119–2128, 2011
36. Bruggeman LA, O’Toole JF, Ross MD, Madhavan SM, Smurzynski M, Wu K, Bosch RJ, Gupta S, Pollak MR, Sedor JR, Kalayjian RC: Plasma apolipoprotein L1 levels do not correlate with CKD. J Am Soc Nephrol 25: 634–644, 2014
37. Folsom AR, Aleksic N, Wang L, Cushman M, Wu KK, White RH: Protein C, antithrombin, and venous thromboembolism incidence: A prospective population-based study. Arterioscler Thromb Vasc Biol 22: 1018–1022, 2002
38. Alonso A, Tang W, Agarwal SK, Soliman EZ, Chamberlain AM, Folsom AR: Hemostatic markers are associated with the risk and prognosis of atrial fibrillation: The ARIC study. Int J Cardiol 155: 217–222, 2012
39. Folsom AR, Ohira T, Yamagishi K, Cushman M: Low protein C and incidence of ischemic stroke and coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study. J Thromb Haemost 7: 1774–1778, 2009
40. Junker R, Heinrich J, Schulte H, Erren M, Assmann G: Hemostasis in normotensive and hypertensive men: Results of the PROCAM study. The prospective cardiovascularMu¨nster study. J Hypertens 16: 917–923, 1998
41. Knobl P, Schernthaner G, Schnack C, Pietschmann P, Proidl S, Prager R, Vukovich T: Haemostatic abnormalities persist despite glycaemic improvement by insulin therapy in lean type 2 diabetic patients. Thromb Haemost 71: 692–697, 1994
42. Vigano S, Mannucci PM, D’Angelo A, Gelfi C, Gensini GF, Rostagno C, Neri Serneri GG: Protein C antigen is not an acute phase reactant and is often high in ischemic heart disease and diabetes. Thromb Haemost 52: 263–266, 1984
43. Gabazza EC, Takeya H, Deguchi H, Sumida Y, TaguchiO,Murata K, Nakatani K, Yano Y, Mohri M, Sata M, Shima T, Nishioka J, Suzuki K: Protein C activation in NIDDM patients. Diabetologia 39: 1455–1461, 1996
44. Sørensen PJ, Knudsen F, Nielsen AH, Dyerberg J: Protein C assays in uremia. Thromb Res 54: 301–310, 1989
45. Esmon CT: The interactions between inflammation and coagulation. Br J Haematol 131: 417–430, 2005